OROXAT patients reached and maintained target Hb

Patients treated with OROXAT reached target Hb levels and remained within the target range

DD, dialysis-dependent; ESA, erythropoiesis-stimulating agent; FAS, full analysis set; Hb, haemoglobin; IDD, incident dialysis-dependent; NDD, non-dialysis-dependent; SE, standard error.

OROXAT patients maintained target Hb on a stable dose

Patients maintained target Hb levels on a stable dose of OROXAT

• The dose of OROXAT remained stable up to Week 104

DD, dialysis-dependent; ESA, erythropoiesis-stimulating agent; FAS, full analysis set; Hb, haemoglobin; IDD, incident dialysis-dependent; NDD, non-dialysis-dependent; SE, standard error.

OROXAT Hb levels comparable with ESA

Patients treated with OROXAT achieved and maintained Hb levels comparable with ESA

The Phase Ill DOLOMITES study evaluated the efficacy and safety of OROXAT compared to darbepoetin-alfa for the treatment of anaemia in NDD patients with stage 3-5 CKD. In the primary endpoint analysis, the study demonstrated non-inferiority of OROXAT to darbepoetin-alfa in the proportion of patients achieving correction of Hb levels during the first 24 weeks of treatment (89.5% vs. 78%, respectively)

CKD, chronic kidney disease; CI, confidence interval; DD, dialysis-dependent; ESA, erythropoiesis-stimulating agent; EOT, end of treatment; Hb, haemoglobin; IDD, incident dialysis-dependent; NDD, non-dialysis-dependent; PPS, per protocol set.

OROXAT reduced use of IV iron compared with ESA

Fewer patients treated with OROXAT received IV iron than those treated with ESA

• EVRENZO was effective without routine use of IV iron in most patients with non-dialysis dependent CKD

CKD, chronic kidney disease; CI, confidence interval; DD, dialysis-dependent; ESA, erythropoiesis-stimulating agent. IV, intravenous; NDD, non-dialysis-dependent.

OROXAT summary of efficacy in NDD

In non-dialysis-dependent CKD, EVRENZO can help your patients achieve and maintain target Hb levels

• EVRENZO demonstrated statistical superiority in Hb correction and maintenance when compared to placebo and was non-inferior to ESAs in the DOLOMITES trial
• Treatment with EVRENZO resulted in a reduced use of IV iron compared with treatment with ESAs

CKD, chronic kidney disease; ESA, erythropoiesis-stimulating agent; Hb, haemoglobin; IV, intravenous.